DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • India
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
524824 logo

Bal Pharma Limited Stock Price

BSE:524824 Community·₹1.8b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

524824 Share Price Performance

₹0
-88.50 (-100.00%)
​
₹0
-88.50 (-100.00%)
​
Price ₹0
Thu, 10 Sep 26
Share Pricen/a

524824 Community Narratives

There are no narratives available yet.
Create Narrative
There are no community narratives available.

Trending Discussion

No trending discussion available.

Recently Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Average dividend payer with slight risk.

4 Risks
2 Rewards
View Full Analysis

Bal Pharma Limited Key Details

₹3.3b

Revenue

₹1.8b

Cost of Revenue

₹1.6b

Gross Profit

₹1.5b

Other Expenses

₹72.1m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Nov 14, 2026
4.53
47.50%
2.16%
193.9%
View Full Analysis

About 524824

Founded
1987
Employees
939
CEO
Shailesh Siroya
WebsiteView website
www.balpharma.com

Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostate enlargement, renal calculi, male infertility, and women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; herbal liver protective and antioxidant; and cardiac care products under the Secremet and Servace brands. In addition, the company offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, and acne treatment, etc.; and various formulations, including tablets, capsules, syrups, suspensions, ophthalmic, creams, and ointments. Further, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company exports its products. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India.

Recent 524824 News & Updates

Recent updates

No updates

Bal Pharma Limited Competitors

AUROPHARMA logo

Aurobindo Pharma

Symbol: NSEI:AUROPHARMA
Market cap: ₹977.5b
500257 logo

Lupin

Symbol: BSE:500257
Market cap: ₹956.5b
500124 logo

Dr. Reddy's Laboratories

Symbol: BSE:500124
Market cap: ₹952.3b
MANKIND logo

Mankind Pharma

Symbol: NSEI:MANKIND
Market cap: ₹935.4b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide